LV12085B - STIMULATIVE BODY STIMULATIVE FACTOR - Google Patents
STIMULATIVE BODY STIMULATIVE FACTOR Download PDFInfo
- Publication number
- LV12085B LV12085B LVP-98-63A LV980063A LV12085B LV 12085 B LV12085 B LV 12085B LV 980063 A LV980063 A LV 980063A LV 12085 B LV12085 B LV 12085B
- Authority
- LV
- Latvia
- Prior art keywords
- ligand
- celis
- flt3
- antigen
- csf
- Prior art date
Links
- 230000004936 stimulating effect Effects 0.000 title description 5
- 102000036639 antigens Human genes 0.000 claims abstract description 70
- 108091007433 antigens Proteins 0.000 claims abstract description 70
- 239000000427 antigen Substances 0.000 claims abstract description 69
- 230000028993 immune response Effects 0.000 claims abstract description 35
- 210000004443 dendritic cell Anatomy 0.000 claims abstract description 30
- 239000012646 vaccine adjuvant Substances 0.000 claims abstract description 11
- 229940124931 vaccine adjuvant Drugs 0.000 claims abstract description 11
- 210000001744 T-lymphocyte Anatomy 0.000 claims abstract description 10
- 210000000130 stem cell Anatomy 0.000 claims abstract 7
- 108700014844 flt3 ligand Proteins 0.000 claims description 74
- 238000000034 method Methods 0.000 claims description 54
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims description 47
- 108010002386 Interleukin-3 Proteins 0.000 claims description 39
- 102000000646 Interleukin-3 Human genes 0.000 claims description 38
- 108010039445 Stem Cell Factor Proteins 0.000 claims description 29
- 102000004388 Interleukin-4 Human genes 0.000 claims description 24
- 108090000978 Interleukin-4 Proteins 0.000 claims description 24
- 238000002360 preparation method Methods 0.000 claims description 23
- 230000003394 haemopoietic effect Effects 0.000 claims description 19
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 claims description 16
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 16
- 229960005486 vaccine Drugs 0.000 claims description 16
- 108090000623 proteins and genes Proteins 0.000 claims description 14
- 102100040247 Tumor necrosis factor Human genes 0.000 claims description 13
- 230000001965 increasing effect Effects 0.000 claims description 13
- 210000004027 cell Anatomy 0.000 claims description 12
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 claims description 11
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 11
- -1 IL -3 Proteins 0.000 claims description 10
- 102000004127 Cytokines Human genes 0.000 claims description 9
- 108090000695 Cytokines Proteins 0.000 claims description 9
- 230000008569 process Effects 0.000 claims description 9
- 201000010099 disease Diseases 0.000 claims description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 8
- 239000003446 ligand Substances 0.000 claims description 8
- 208000035473 Communicable disease Diseases 0.000 claims description 6
- 102000004169 proteins and genes Human genes 0.000 claims description 6
- 102000006354 HLA-DR Antigens Human genes 0.000 claims description 5
- 108010058597 HLA-DR Antigens Proteins 0.000 claims description 5
- 208000015181 infectious disease Diseases 0.000 claims description 4
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 claims description 2
- 108010002352 Interleukin-1 Proteins 0.000 claims description 2
- 102000000589 Interleukin-1 Human genes 0.000 claims description 2
- 102100027754 Mast/stem cell growth factor receptor Kit Human genes 0.000 claims description 2
- 102000015215 Stem Cell Factor Human genes 0.000 claims 6
- 229910045601 alloy Inorganic materials 0.000 claims 6
- 239000000956 alloy Substances 0.000 claims 6
- 210000003995 blood forming stem cell Anatomy 0.000 claims 3
- 210000004524 haematopoietic cell Anatomy 0.000 claims 2
- 230000003211 malignant effect Effects 0.000 claims 2
- 241000124008 Mammalia Species 0.000 claims 1
- 238000005275 alloying Methods 0.000 claims 1
- 230000004663 cell proliferation Effects 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 abstract description 29
- 238000001727 in vivo Methods 0.000 abstract description 15
- 101710162577 Fms-related tyrosine kinase 3 ligand protein Proteins 0.000 abstract description 6
- 102100020715 Fms-related tyrosine kinase 3 ligand protein Human genes 0.000 abstract description 6
- 210000003958 hematopoietic stem cell Anatomy 0.000 abstract 1
- 230000003612 virological effect Effects 0.000 abstract 1
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 33
- 102100020880 Kit ligand Human genes 0.000 description 24
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 20
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 20
- 150000001413 amino acids Chemical group 0.000 description 16
- 230000004927 fusion Effects 0.000 description 14
- 241000699670 Mus sp. Species 0.000 description 12
- 101001033279 Homo sapiens Interleukin-3 Proteins 0.000 description 10
- 230000003190 augmentative effect Effects 0.000 description 9
- 230000001404 mediated effect Effects 0.000 description 9
- 102000055276 human IL3 Human genes 0.000 description 8
- 210000001519 tissue Anatomy 0.000 description 8
- 239000011324 bead Substances 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- 210000005259 peripheral blood Anatomy 0.000 description 7
- 239000011886 peripheral blood Substances 0.000 description 7
- 101000746373 Homo sapiens Granulocyte-macrophage colony-stimulating factor Proteins 0.000 description 6
- 102000046157 human CSF2 Human genes 0.000 description 6
- 230000004044 response Effects 0.000 description 6
- 108090001008 Avidin Proteins 0.000 description 5
- 239000002671 adjuvant Substances 0.000 description 5
- 102000023732 binding proteins Human genes 0.000 description 5
- 108091008324 binding proteins Proteins 0.000 description 5
- 239000001963 growth medium Substances 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 210000002540 macrophage Anatomy 0.000 description 5
- 235000018102 proteins Nutrition 0.000 description 5
- 108010038379 sargramostim Proteins 0.000 description 5
- 238000006467 substitution reaction Methods 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 235000001014 amino acid Nutrition 0.000 description 4
- 238000002617 apheresis Methods 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 230000002708 enhancing effect Effects 0.000 description 4
- 108020001507 fusion proteins Proteins 0.000 description 4
- 102000037865 fusion proteins Human genes 0.000 description 4
- 230000005847 immunogenicity Effects 0.000 description 4
- 230000001976 improved effect Effects 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 229920001184 polypeptide Polymers 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- RANONBLIHMVXAJ-UHFFFAOYSA-N 4-hydroxycyclophosphamide Chemical compound OC1CCOP(=O)(N(CCCl)CCCl)N1 RANONBLIHMVXAJ-UHFFFAOYSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 3
- 101001002709 Homo sapiens Interleukin-4 Proteins 0.000 description 3
- 101000716729 Homo sapiens Kit ligand Proteins 0.000 description 3
- 101100335081 Mus musculus Flt3 gene Proteins 0.000 description 3
- 210000001185 bone marrow Anatomy 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 229960002949 fluorouracil Drugs 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 239000003102 growth factor Substances 0.000 description 3
- 102000055229 human IL4 Human genes 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 230000002163 immunogen Effects 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 229940087875 leukine Drugs 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 230000002463 transducing effect Effects 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 102000016355 Granulocyte-Macrophage Colony-Stimulating Factor Receptors Human genes 0.000 description 2
- 108010092372 Granulocyte-Macrophage Colony-Stimulating Factor Receptors Proteins 0.000 description 2
- 101000932480 Homo sapiens Fms-related tyrosine kinase 3 ligand Proteins 0.000 description 2
- 102000010787 Interleukin-4 Receptors Human genes 0.000 description 2
- 108010038486 Interleukin-4 Receptors Proteins 0.000 description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 102000016971 Proto-Oncogene Proteins c-kit Human genes 0.000 description 2
- 108010014608 Proto-Oncogene Proteins c-kit Proteins 0.000 description 2
- 108010090804 Streptavidin Proteins 0.000 description 2
- 101150052863 THY1 gene Proteins 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 239000011149 active material Substances 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N aspartic acid group Chemical group N[C@@H](CC(=O)O)C(=O)O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 239000002577 cryoprotective agent Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 230000001483 mobilizing effect Effects 0.000 description 2
- 230000001613 neoplastic effect Effects 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 229960002530 sargramostim Drugs 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- 239000012808 vapor phase Substances 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 108700028369 Alleles Proteins 0.000 description 1
- 241000212384 Bifora Species 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 206010008631 Cholera Diseases 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 108010092408 Eosinophil Peroxidase Proteins 0.000 description 1
- 102100028471 Eosinophil peroxidase Human genes 0.000 description 1
- 201000008808 Fibrosarcoma Diseases 0.000 description 1
- 208000009329 Graft vs Host Disease Diseases 0.000 description 1
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 1
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 101000746367 Homo sapiens Granulocyte colony-stimulating factor Proteins 0.000 description 1
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 description 1
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 108010002586 Interleukin-7 Proteins 0.000 description 1
- 108090001007 Interleukin-8 Proteins 0.000 description 1
- 108010002335 Interleukin-9 Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 239000007760 Iscove's Modified Dulbecco's Medium Substances 0.000 description 1
- 101710177504 Kit ligand Proteins 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- 102100033486 Lymphocyte antigen 75 Human genes 0.000 description 1
- 101710157884 Lymphocyte antigen 75 Proteins 0.000 description 1
- 241000867077 Macropes Species 0.000 description 1
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- PPQNQXQZIWHJRB-UHFFFAOYSA-N Methylcholanthrene Chemical compound C1=CC=C2C3=CC4=CC=C(C)C(CC5)=C4C5=C3C=CC2=C1 PPQNQXQZIWHJRB-UHFFFAOYSA-N 0.000 description 1
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 description 1
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 208000000474 Poliomyelitis Diseases 0.000 description 1
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 1
- 101710146873 Receptor-binding protein Proteins 0.000 description 1
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 102000004338 Transferrin Human genes 0.000 description 1
- 108090000901 Transferrin Proteins 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 230000002152 alkylating effect Effects 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000030741 antigen processing and presentation Effects 0.000 description 1
- 230000005975 antitumor immune response Effects 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 230000003416 augmentation Effects 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 238000004163 cytometry Methods 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 210000003617 erythrocyte membrane Anatomy 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 238000010230 functional analysis Methods 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 208000024908 graft versus host disease Diseases 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 230000008348 humoral response Effects 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000000091 immunopotentiator Effects 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000000266 injurious effect Effects 0.000 description 1
- 229940028885 interleukin-4 Drugs 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- ZAHQPTJLOCWVPG-UHFFFAOYSA-N mitoxantrone dihydrochloride Chemical compound Cl.Cl.O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO ZAHQPTJLOCWVPG-UHFFFAOYSA-N 0.000 description 1
- PJUIMOJAAPLTRJ-UHFFFAOYSA-N monothioglycerol Chemical compound OCC(O)CS PJUIMOJAAPLTRJ-UHFFFAOYSA-N 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000006337 proteolytic cleavage Effects 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 239000012581 transferrin Substances 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 230000037455 tumor specific immune response Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/125—Stem cell factor [SCF], c-kit ligand [KL]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/22—Colony stimulating factors (G-CSF, GM-CSF)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/24—Interferons [IFN]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/26—Flt-3 ligand (CD135L, flk-2 ligand)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Mycology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Compositions Of Macromolecular Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US53914295A | 1995-10-04 | 1995-10-04 | |
PCT/US1996/015990 WO1997012633A1 (en) | 1995-10-04 | 1996-10-03 | Dendritic cell stimulatory factor |
Publications (2)
Publication Number | Publication Date |
---|---|
LV12085A LV12085A (lv) | 1998-07-20 |
LV12085B true LV12085B (en) | 1998-09-20 |
Family
ID=24149974
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
LVP-98-63A LV12085B (en) | 1995-10-04 | 1998-04-02 | STIMULATIVE BODY STIMULATIVE FACTOR |
Country Status (23)
Country | Link |
---|---|
EP (1) | EP0871487B1 (de) |
JP (1) | JP3631496B2 (de) |
KR (2) | KR100676792B1 (de) |
CN (1) | CN1172718C (de) |
AT (1) | ATE432085T1 (de) |
AU (1) | AU697539B2 (de) |
BR (1) | BR9610802A (de) |
CA (1) | CA2232865A1 (de) |
CZ (1) | CZ97798A3 (de) |
DE (1) | DE69637942D1 (de) |
EA (1) | EA199800272A1 (de) |
EE (1) | EE9800105A (de) |
ES (1) | ES2323818T3 (de) |
IS (1) | IS4703A (de) |
LV (1) | LV12085B (de) |
NO (1) | NO981374L (de) |
NZ (1) | NZ321039A (de) |
PL (1) | PL187329B1 (de) |
RO (1) | RO120579B1 (de) |
SI (1) | SI9620116A (de) |
SK (1) | SK40898A3 (de) |
TR (1) | TR199800607T1 (de) |
WO (1) | WO1997012633A1 (de) |
Families Citing this family (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030026782A1 (en) | 1995-02-07 | 2003-02-06 | Arthur M. Krieg | Immunomodulatory oligonucleotides |
US6429199B1 (en) | 1994-07-15 | 2002-08-06 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules for activating dendritic cells |
US6207646B1 (en) | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
US9068164B1 (en) * | 1995-02-02 | 2015-06-30 | Tristem Trading (Cyprus) Limited | Method of preparing an undifferentiated cell |
AU705647B2 (en) * | 1996-07-10 | 1999-05-27 | Immunex Corporation | Method of activating dendritic cells |
AUPO388396A0 (en) * | 1996-11-27 | 1996-12-19 | Ludwig Institute For Cancer Research | Cellular adjuvant |
AU7835898A (en) * | 1997-06-17 | 1999-01-04 | Immunex Corporation | A method of enhancing antigen-specific peripheral immune tolerance |
FR2782524B1 (fr) * | 1998-08-21 | 2002-07-19 | Roussy Inst Gustave | Methodes d'activation de cellules tueuses naturelles (nk) et moyens de mise en oeuvre |
US6849452B1 (en) | 1998-03-03 | 2005-02-01 | Institut Gustave Roussy | Methods for activating natural killer (NK) cells and means for carrying out said methods |
FR2775692B1 (fr) * | 1998-03-03 | 2000-06-16 | Roussy Inst Gustave | Methodes d'activation de cellules tueuses naturelles (nk) et moyens de mise en oeuvre |
WO1999061056A2 (en) | 1998-05-22 | 1999-12-02 | Loeb Health Research Institute At The Ottawa Hospital | Methods and products for inducing mucosal immunity |
AU4423799A (en) * | 1998-06-04 | 1999-12-20 | Cornell Research Foundation Inc. | Methods and agents for modulating the immune response and inflammation involvingmonocyte and dendritic cell membrane proteins |
US6291661B1 (en) | 1998-07-02 | 2001-09-18 | Immunex Corporation | flt3-L mutants and method of use |
WO2000012122A2 (de) * | 1998-08-27 | 2000-03-09 | Universitätsklinikum Freiburg | Niedermolekulare fragmente der hyaluronsäure zur herstellung von impfstoffen |
GB9827604D0 (en) * | 1998-12-15 | 1999-02-10 | Lorantis Ltd | Methods of immunosuppression |
WO2001009303A2 (en) * | 1999-07-30 | 2001-02-08 | Vical Inc. | Flt-3 LIGAND-ENCODING POLYNUCLEOTIDE AS A POLYNUCLEOTIDE-BASED VACCINE ENHANCER |
CA2389680A1 (en) * | 1999-11-03 | 2001-05-10 | Powderject Vaccines, Inc. | Nucleic acid vaccine compositions having a mammalian cd80/cd86 gene promoter driving antigen expression |
WO2001062275A1 (en) * | 2000-02-24 | 2001-08-30 | The Board Of Trustees Of The Leland Stanford Junior University | Adjuvant treatment by in vivo activation of dendritic cells |
AU5574001A (en) * | 2000-04-25 | 2001-11-07 | Immunex Corp | Method for treatment of tumors using photodynamic therapy |
WO2002036141A2 (en) * | 2000-11-02 | 2002-05-10 | Immunex Corporation | Method of enhancing lymphocyte-mediated immune responses |
AU2002225927A1 (en) * | 2000-11-17 | 2002-05-27 | Immunex Corporation | Chemoattractant recruitment of dendritic cells for enhancement of immunization |
CN102973928B (zh) * | 2001-09-06 | 2019-03-15 | 西北生物治疗药物公司 | 引发单核树突细胞和t细胞th-1应答的组合物和方法 |
KR100490308B1 (ko) * | 2002-02-25 | 2005-05-17 | 크레아젠 주식회사 | 면역 치료용 성숙화된 수지상 세포 백신의 제조방법 |
CA2480128A1 (en) * | 2002-03-26 | 2003-10-09 | Immunex Corporation | Methods of using flt3-ligand in immunization protocols |
US20050084967A1 (en) | 2002-06-28 | 2005-04-21 | Xcyte Therapies, Inc. | Compositions and methods for eliminating undesired subpopulations of T cells in patients with immunological defects related to autoimmunity and organ or hematopoietic stem cell transplantation |
KR100522526B1 (ko) * | 2002-11-28 | 2005-10-19 | 주식회사 바이넥스 | 면역 치료용 수지상 세포의 제조방법 |
KR100614220B1 (ko) * | 2004-11-08 | 2006-08-21 | 고려대학교 산학협력단 | Flt3 리간드 유전자를 발현하는 살모넬라 균주 및 이를함유하는 항암 치료용 조성물 |
DE102005016234B4 (de) * | 2005-04-08 | 2008-05-15 | Tgc Biomics Gmbh | Verfahren zur Einschleusung von exogenem Antigen in den MHC I-Präsentationsweg von Zellen |
KR100818215B1 (ko) | 2006-10-11 | 2008-04-01 | 재단법인서울대학교산학협력재단 | Cd34양성 줄기세포로부터 t 임파구 전구체를 제조하는 방법 |
KR101264811B1 (ko) | 2011-05-20 | 2013-05-15 | 충남대학교산학협력단 | 마이코박테리움 압세수스의 MAB0981c 단백질을 이용한 수지상 세포의 성숙방법 |
US11850279B2 (en) | 2016-07-13 | 2023-12-26 | Ohio State Innovation Foundation | Platforms and methods for optimizing host antigen presentation and host antitumor and antipathogen immunity |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US826250A (en) | 1905-12-20 | 1906-07-17 | Albert Huck | Switch for toy railways. |
US4714680B1 (en) | 1984-02-06 | 1995-06-27 | Univ Johns Hopkins | Human stem cells |
US5391485A (en) | 1985-08-06 | 1995-02-21 | Immunex Corporation | DNAs encoding analog GM-CSF molecules displaying resistance to proteases which cleave at adjacent dibasic residues |
EP0275598B1 (de) | 1986-12-16 | 1998-01-07 | Gist-Brocades N.V. | Molekulare Klonierung und Expression von menschlichem IL-3 |
OA09736A (en) | 1987-02-18 | 1993-11-30 | Schering Biotech Corp | "Human interleukin-3 and muteins thereof". |
WO1989003881A1 (en) | 1987-10-30 | 1989-05-05 | Immunex Corporation | Nonglycosylated analogs of human colony stimulating factors |
US5108910A (en) | 1989-08-22 | 1992-04-28 | Immunex Corporation | DNA sequences encoding fusion proteins comprising GM-CSF and IL-3 |
US5073627A (en) | 1989-08-22 | 1991-12-17 | Immunex Corporation | Fusion proteins comprising GM-CSF and IL-3 |
SG43009A1 (en) | 1989-10-16 | 1997-10-17 | Amgen Inc | Stem cell factor |
US5199942A (en) | 1991-06-07 | 1993-04-06 | Immunex Corporation | Method for improving autologous transplantation |
CA2122141C (en) | 1991-10-23 | 2007-07-17 | Shelly Heimfeld | Methods for selectively expanding stem cells |
US5554512A (en) | 1993-05-24 | 1996-09-10 | Immunex Corporation | Ligands for flt3 receptors |
CZ307995A3 (en) * | 1993-05-24 | 1996-10-16 | Immunex Corp | Ligands for flt3 receptors |
US5405772A (en) * | 1993-06-18 | 1995-04-11 | Amgen Inc. | Medium for long-term proliferation and development of cells |
-
1996
- 1996-10-03 BR BR9610802A patent/BR9610802A/pt unknown
- 1996-10-03 SI SI9620116A patent/SI9620116A/sl unknown
- 1996-10-03 PL PL96325964A patent/PL187329B1/pl not_active IP Right Cessation
- 1996-10-03 TR TR1998/00607T patent/TR199800607T1/xx unknown
- 1996-10-03 CA CA002232865A patent/CA2232865A1/en not_active Abandoned
- 1996-10-03 CN CNB96197351XA patent/CN1172718C/zh not_active Expired - Fee Related
- 1996-10-03 DE DE69637942T patent/DE69637942D1/de not_active Expired - Lifetime
- 1996-10-03 NZ NZ321039A patent/NZ321039A/en unknown
- 1996-10-03 JP JP51449097A patent/JP3631496B2/ja not_active Expired - Fee Related
- 1996-10-03 KR KR1020047011434A patent/KR100676792B1/ko not_active IP Right Cessation
- 1996-10-03 WO PCT/US1996/015990 patent/WO1997012633A1/en not_active Application Discontinuation
- 1996-10-03 ES ES96936216T patent/ES2323818T3/es not_active Expired - Lifetime
- 1996-10-03 KR KR10-1998-0702286A patent/KR100514957B1/ko not_active IP Right Cessation
- 1996-10-03 CZ CZ98977A patent/CZ97798A3/cs unknown
- 1996-10-03 AT AT96936216T patent/ATE432085T1/de not_active IP Right Cessation
- 1996-10-03 RO RO98-00824A patent/RO120579B1/ro unknown
- 1996-10-03 EA EA199800272A patent/EA199800272A1/ru unknown
- 1996-10-03 AU AU73922/96A patent/AU697539B2/en not_active Ceased
- 1996-10-03 EP EP96936216A patent/EP0871487B1/de not_active Expired - Lifetime
- 1996-10-03 SK SK408-98A patent/SK40898A3/sk unknown
- 1996-10-03 EE EE9800105A patent/EE9800105A/xx unknown
-
1998
- 1998-03-26 NO NO981374A patent/NO981374L/no unknown
- 1998-03-26 IS IS4703A patent/IS4703A/is unknown
- 1998-04-02 LV LVP-98-63A patent/LV12085B/en unknown
Also Published As
Publication number | Publication date |
---|---|
PL325964A1 (en) | 1998-08-17 |
EE9800105A (et) | 1998-10-15 |
KR100676792B1 (ko) | 2007-02-02 |
KR19990063818A (ko) | 1999-07-26 |
NZ321039A (en) | 2001-03-30 |
CN1229359A (zh) | 1999-09-22 |
EP0871487A4 (de) | 2004-09-01 |
AU7392296A (en) | 1997-04-28 |
ATE432085T1 (de) | 2009-06-15 |
LV12085A (lv) | 1998-07-20 |
CZ97798A3 (cs) | 1999-02-17 |
AU697539B2 (en) | 1998-10-08 |
NO981374D0 (no) | 1998-03-26 |
BR9610802A (pt) | 1999-07-13 |
CN1172718C (zh) | 2004-10-27 |
SI9620116A (sl) | 1999-08-31 |
PL187329B1 (pl) | 2004-06-30 |
JPH11513389A (ja) | 1999-11-16 |
JP3631496B2 (ja) | 2005-03-23 |
CA2232865A1 (en) | 1997-04-10 |
KR100514957B1 (ko) | 2005-11-25 |
TR199800607T1 (xx) | 1998-06-22 |
NO981374L (no) | 1998-06-03 |
WO1997012633A1 (en) | 1997-04-10 |
ES2323818T3 (es) | 2009-07-24 |
SK40898A3 (en) | 1999-04-13 |
EA199800272A1 (ru) | 1998-10-29 |
RO120579B1 (ro) | 2006-04-28 |
EP0871487B1 (de) | 2009-05-27 |
IS4703A (is) | 1998-03-26 |
KR20040079421A (ko) | 2004-09-14 |
EP0871487A1 (de) | 1998-10-21 |
DE69637942D1 (de) | 2009-07-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU697539B2 (en) | Dendritic cell stimulatory factor | |
US20060292166A1 (en) | Vaccine composition comprising Flt3-ligand | |
US20090075886A1 (en) | Dendritic cell stimulatory factor | |
US6017527A (en) | Activated dendritic cells and methods for their activation | |
CA2259140C (en) | Method of activating dendritic cells | |
Liau et al. | Treatment of intracranial gliomas with bone marrow—derived dendritic cells pulsed with tumor antigens | |
US20020111475A1 (en) | Flt3-L mutants and methods of use | |
US20030124091A1 (en) | Endothelial cell derived hematopoietic growth factor | |
US20030077263A1 (en) | Method of activating dendritic cells | |
US7150992B1 (en) | Methods of preparing dendritic cells with flt3-ligand and antigen | |
US20040033213A1 (en) | Methods of modulating dendritic cells using adjuvants | |
MXPA98002464A (en) | Dendrit cellular stimulating factor | |
US20050048645A1 (en) | Method of treating or preventing disease characterized by cryptococcus neoformans infection | |
MXPA96003788A (en) | Cultivation and extracorporal cellular transplantation equipment containing linking f |